Severe Asthma Reduced in Phase 3 Benralizumab Tests – Lung Disease News


Lung Disease News

Severe Asthma Reduced in Phase 3 Benralizumab Tests
Lung Disease News
AstraZeneca recently announced that the new severe asthma medicine benralizumab met the primary endpoints in two Phase 3 registration trials. Findings of the trials called SIROCCO and CALIMA, revealed that the monoclonal antibody compound was well …

View full post on asthma – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *